OasisLMS

1. To register, press the "Get Started" button.
2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login."
3. After registering for the course, go to the "Bundled Courses" tab to access each topic you are interested in.

• Moderator: Sahil A. Parikh, MD, FSCAI
• Coronary DCB Clinical Trials: Key Data and Their Implication for Practice, Sahil A. Parikh, MD, FSCAI
  
• Getting It Right: Using IVUS, Lesions, Evan Shlofmitz, DO
• Case: Using DCBs to Treat In-Stent Restenosis, Kate Kearney, MD, FSCAI
• DCB Billing and Reimbursement, Monica Wright, DPA, MHA, CPC, CPMA, CPCO
• Panelists: Brian Bergmark, MD, FSCAI; Wayne B. Batchelor, MD, FSCAI

Part 2: Coronary DCBs in De Novo Lesions, Small Vessel, and Bifurcation: The European Experience

• Moderator: Azeem Latib, MD, FSCAI
• Case: De Novo Lesion, Antonio Colombo, MD, MSCAI
• Case: Long Lesion Involving Bifurcation in Patient with ACS, Tanveer Rab, MD, MSCAI
• Case: Small Vessel, Bernardo Cortese, MD, FSCAI

• Moderators: Sahil A. Parikh, MD, FSCAI; Ziad A. Ali, MD, PhD, FSCAI
• Case: Treating Single-Layer ISR, Brian Bergmark, MD, FSCAI
• Case: Double-Layer ISR, J. Dawn Abbott, MD, MSCAI
• Case: Treating Stent Failure with DCBs, Underinflation or Lack of Calcium Management, Emily Larnard, MD

• Discuss key data from coronary drug-coated balloon (DCB) clinical trials and their implications for clinical practice.
• Select appropriate patients for coronary DCB’s.
• Plan for deployment of coronary DCB’s, including step-by-step imaging guidance and lesions preparation.
• Examine cases of in-stent restenosis (ISR), including single-layer, double-layer, and stent failure. 
• Explore other evidence-based applications of coronary DCB’s.

• Sahil Parikh: Boston Scientific Corp. - Advisory Board/Board Member 
  

• Kristen Perry: No relevant financial relationships with ineligible companies.

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.